Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SIGNAL GEC-101: Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer

NCT07565857 is registered in ClinicalTrials.gov with Natera, Inc. as lead sponsor.

NCT NCT07565857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07565857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SIGNAL GEC-101: Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer
Lead sponsor
Natera, Inc.
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
September 30, 2034
Enrollment
1,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastric-esophageal cancer